The CDC’s 2021 Sexually Transmitted Infections Treatment Guidelines identify doxycycline 100 mg orally twice daily or tetracycline 500 mg orally four times daily, each for 28 days, as the only acceptable alternatives to penicillin for late latent syphilis or syphilis of unknown duration in nonpregnant patients with penicillin allergy. The guidelines do not designate either regimen as preferred and note that the effectiveness of alternatives to penicillin for latent syphilis has not been well documented, particularly among persons with HIV infection. These regimens require close clinical and serologic follow-up, with quantitative nontreponemal testing recommended at 6, 12, and 24 months. For clearly defined early latent syphilis, nonpregnant patients with penicillin allergy should respond to alternative antibiotics recommended for primary and secondary syphilis. Ceftriaxone might be effective for latent syphilis; however, its optimal dose and duration remain undefined, and treatment decisions should involve specialist consultation. Patients with penicillin allergy whose adherence or follow-up cannot be ensured, as well as pregnant patients with penicillin allergy, should undergo desensitization and receive penicillin G. [1]
A 2024 meta-analysis evaluated nonpenicillin treatment strategies for nonneurological syphilis across 27 comparative studies involving 6,710 patients, including patients with early and late latent syphilis. Searches included six databases from inception through August 28, 2023; the primary outcome was serological cure, most commonly defined as a ≥4-fold decline in nontreponemal antibody titers, although assessment time points varied. Across nine studies comparing doxycycline with benzathine penicillin G, serological cure rates did not differ significantly (pooled odds ratio [OR] 0.82; 95% confidence interval [CI] 0.61 to 1.10; I²= 1%). Doxycycline regimens generally consisted of oral doses of ≥100 mg twice daily for 14 to 28 days, depending on disease stage. Similarly, five studies comparing ceftriaxone with benzathine penicillin G found no significant difference in serological cure (pooled OR 1.66; 95% CI 0.97 to 2.84; I²= 0%). Although azithromycin also demonstrated no significant difference from penicillin, the authors acknowledged that CDC guidance discourages its use because of antimicrobial resistance concerns. Limitations included predominantly nonrandomized studies (17/27), variable treatment regimens and definitions of serological cure, and incomplete adverse event and reinfection data. These pooled comparisons encompassed multiple syphilis stages and did not establish a preferred alternative specifically for latent syphilis. [2]
A 2026 network meta-analysis evaluated alternative antibiotic regimens for early and late syphilis, including 14 randomized controlled trials (RCTs; N= 2,280) and 20 observational studies (N= 6,895). Thirteen RCTs involving 1,623 participants and 10 treatments contributed to the network meta-analysis, which assessed cure at 12 months or the nearest reported time point; all studies incorporated serologic response into their cure definitions. Doxycycline monotherapy did not demonstrate a statistically significant difference in cure compared with benzathine penicillin G (OR 6.88; 95% credible interval [CrI] 0.14 to 625.93), although the point estimate favored doxycycline. Observational meta-analyses likewise found no statistically significant differences between benzathine penicillin and doxycycline or other tetracyclines. The review described doxycycline 100 mg orally twice daily for 14 days as a recommended alternative for early latent syphilis and a 28-day course for late latent syphilis. However, insufficient reporting of syphilis stage prevented the planned stage-specific analyses, and evidence certainty was generally low for RCTs and very low for observational studies because of risk of bias and imprecision; consequently, noninferiority of alternative regimens could not be established. The authors concluded that doxycycline remained the best-supported alternative to benzathine penicillin for early and late latent syphilis in nonpregnant adults and adolescents, while acknowledging potential adherence challenges and the limitations of the available evidence. [3]
The 2016 World Health Organization (WHO) guidelines, which remain applicable to syphilis treatment in nonpregnant adults and adolescents, distinguish early latent syphilis (infection of no more than 2 years’ duration) from late latent syphilis or infection of unknown duration. For early latent syphilis, WHO recommends benzathine penicillin G 2.4 million units intramuscularly once. When benzathine or procaine penicillin cannot be used or is unavailable, WHO suggests doxycycline 100 mg orally twice daily for 14 days or ceftriaxone 1 g intramuscularly daily for 10 to 14 days; doxycycline is preferred over ceftriaxone because of its lower cost and oral administration. Azithromycin 2 g orally once is suggested only in special circumstances when local susceptibility is likely. For late latent syphilis or infection of unknown duration, WHO recommends benzathine penicillin G 2.4 million units intramuscularly weekly for 3 consecutive weeks. When penicillin cannot be used, including allergy for which desensitization is not possible, or is unavailable, WHO suggests doxycycline 100 mg orally twice daily for 30 days. These alternative-treatment recommendations are conditional and supported by very low-quality evidence. [4]